MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function Roland Kolbeck, PhD, Alexander Kozhich,

Slides:

Advertisements

Similar presentations

Maria B. Sukkar, PhD, Shaoping Xie, PhD, Nadia M

Advertisements

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses Chris J. Corrigan, MD, PhD, Wei.

Identification of drug- and drug-metabolite immune responses originating from both naive and memory T cells Andrew Gibson, MRes, Lee Faulkner, PhD, Sally.

Surface availability of beta-glucans is critical determinant of host immune response to Cladosporium cladosporioides Rachael A. Mintz-Cole, PhD, Eric.

Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations Marina Pretolani, PharmD,

Critical link between glycogen synthase kinase 3β and forkhead box P3 in patients with chronic rhinosinusitis with nasal polyps Xingmei Wu, MD, Sihua.

IL-4 induces IL-13–independent allergic airway inflammation

Advances in food allergy in 2015

IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,

Diagnosis and management of anaphylaxis in precision medicine

Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation

Expression of IL-4 receptor α on smooth muscle cells is not necessary for development of experimental allergic asthma Frank Kirstein, PhD, William G.C.

Frank Kirstein, PhD, Natalie E

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels Miguel L. Stein, MD, Joyce M. Villanueva,

Eosinophil extracellular DNA traps in skin diseases

Role of IL-9 in the pathophysiology of allergic diseases

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Allergic airway disease is unaffected by the absence of IL-4Rα–dependent alternatively activated macrophages Natalie E. Nieuwenhuizen, PhD, Frank Kirstein,

Is 9 more than 2 also in allergic airway inflammation?

Inflammation in common variable immunodeficiency is associated with a distinct CD8+ response to cytomegalovirus Sayed Mahdi Marashi, PhD, Mohammad Raeiszadeh,

Human mast cells arise from a common circulating progenitor

IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis Todd M. Wilson, DO, Irina Maric, MD, Juhi Shukla, MSc, Margaret Brown, BS,

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses Chris J. Corrigan, MD, PhD, Wei.

Prime role of IL-17A in neutrophilia and airway smooth muscle contraction in a house dust mite–induced allergic asthma model Julie Chesné, PhD, Faouzi.

Airway smooth muscle remodeling is a dynamic process in severe long-standing asthma Muhannad Hassan, MD, Taisuke Jo, MD, PhD, Paul-André Risse, PhD,

Frank Kirstein, PhD, Natalie E

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Susan C. Foley, MD, David Préfontaine, MSc, Qutayba Hamid, MD, PhD

Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis Chisa Nakashima, MD, Atsushi Otsuka, MD, PhD, Akihiko.

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

Physician needs in health informatics: Just ask the docs

Human mast cells drive memory CD4+ T cells toward an inflammatory IL-22+ phenotype Nicolas Gaudenzio, PhD, Camille Laurent, MD, Salvatore Valitutti,

Surface availability of beta-glucans is critical determinant of host immune response to Cladosporium cladosporioides Rachael A. Mintz-Cole, PhD, Eric.

Michel Laviolette, MD, David L

Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis Shunya Mashiko, BPharm, Salim Bouguermouh, MD, PhD, Manuel.

Biologics and biomarkers for asthma, urticaria, and nasal polyposis

Andrea Bree, BS, Franklin J

Airway smooth muscle remodeling is a dynamic process in severe long-standing asthma Muhannad Hassan, MD, Taisuke Jo, MD, PhD, Paul-André Risse, PhD,

Identification of drug- and drug-metabolite immune responses originating from both naive and memory T cells Andrew Gibson, MRes, Lee Faulkner, PhD, Sally.

Sarita Sehra, PhD, Weiguo Yao, PhD, Evelyn T. Nguyen, MS, Nicole L

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

The Editors' Choice Journal of Allergy and Clinical Immunology

Allergic skin sensitization promotes eosinophilic esophagitis through the IL-33–basophil axis in mice Nicholas Venturelli, BS, Willem S. Lexmond, MD,

The role of the mast cell in the pathophysiology of asthma

IL-13 mediates IL-33–dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells Deepti R. Nagarkar, PhD, Vladimir Ramirez-Carrozzi,

Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules Josiane S. Neves,

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps Tetsuji Takabayashi, MD, Atsushi Kato, PhD,

CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma Kawa Amin, PhD, Christer Janson, MD, PhD, Ilkka Harvima, MD,

Novel allergic asthma model demonstrates ST2-dependent dendritic cell targeting by cypress pollen Lucia Gabriele, BS, Giovanna Schiavoni, BS, Fabrizio.

IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,

Xin-Zi Tang, PhD, James B. Jung, BS, Christopher D.C. Allen, PhD

Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy.

IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets Sven Létourneau, DPhil, Carsten Krieg, PhD, Giuseppe Pantaleo,

Lei Wang, MD, PhD, Jesse P. Joad, MD, Caiyun Zhong, MD, PhD, Kent E

Effect of IL-13 receptor α2 levels on the biological activity of IL-13 variant R110Q Allison-Lynn Andrews, PhD, Fabio Bucchieri, MD, Kazuhiko Arima, MD,

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis Iris M. Otani, MD, Arjun A. Anilkumar,

The eosinophil surface receptor epidermal growth factor–like module containing mucin- like hormone receptor 1 (EMR1): A novel therapeutic target for eosinophilic.

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Biju Thomas, MD, Robert Anthony Hirst, PhD, Mina H

Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways Ryszard Dworski, MD, PhD, Hans-Uwe Simon, MD, PhD, Aimee Hoskins,

Reply Journal of Allergy and Clinical Immunology

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Cigarette smoke exposure is associated with vitamin D3 deficiencies in patients with chronic rhinosinusitis Jennifer K. Mulligan, PhD, Whitney Nagel,

The eosinophil surface receptor epidermal growth factor–like module containing mucin- like hormone receptor 1 (EMR1): A novel therapeutic target for eosinophilic.

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma Cecilia K. Andersson, PhD, Anders Bergqvist, MSc, Michiko Mori,

Presentation transcript:

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function Roland Kolbeck, PhD, Alexander Kozhich, PhD, Masamichi Koike, PhD, Li Peng, PhD, Cecilia K. Andersson, PhD, Melissa M. Damschroder, BA, Jennifer L. Reed, PhD, Robert Woods, MS, William W. Dall'Acqua, PhD, Geoffrey L. Stephens, PhD, Jonas S. Erjefalt, PhD, Leif Bjermer, MD, Alison A. Humbles, PhD, David Gossage, MD, Herren Wu, PhD, Peter A. Kiener, PhD, George L. Spitalny, PhD, Charles R. Mackay, PhD, Nestor A. Molfino, MD, Anthony J. Coyle, PhD Journal of Allergy and Clinical Immunology Volume 125, Issue 6, Pages 1344-1353.e2 (June 2010) DOI: 10.1016/j.jaci.2010.04.004 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Interaction of MEDI-563 with IL-5Rα. A, IL5RA mRNA expression on human immune cells. B, Human IL-5Rα expression on basophils (n = 2), eosinophils (n = 3), and BMMNCs (n = 4) using MEDI-563 F(ab′)2 or an irrelevant control antibody (shaded areas). C, Binding of parent αIL-5Rα mAb to human and cynomolgus monkey (Cyno) eosinophils. MFI, Mean fluorescence intensity. D, Inhibition of IL-5–induced CTLL-2 cell proliferation (± SD). Shown are representative experiments. n, Number of experiments performed. Journal of Allergy and Clinical Immunology 2010 125, 1344-1353.e2DOI: (10.1016/j.jaci.2010.04.004) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Identification of the MEDI-563 binding epitope to human IL-5Rα. A, MEDI-563 binding to extracellular chimeric human IL-5Rα (light green) and murine IL-5Rα (dark green) variants. D, Domain. B, Sequence alignment of murine, human, and cynomolgus monkey (Cyno) IL-5Rα D1 (differences are shown as dashes; segments A [SA], B [SB], and C [SC] are boxed). C, MEDI-563 binding to IL-5Rα segment variants. D, Isoleucin 61 (I61) of human IL-5Rα is the critical residue for MEDI-563 binding. I61 is shown in red in Fig 2, B. Journal of Allergy and Clinical Immunology 2010 125, 1344-1353.e2DOI: (10.1016/j.jaci.2010.04.004) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Enhanced ADCC of MEDI-563. A, MEDI-563–mediated ADCC of human eosinophils (EC50 = 0.9 pmol/L, n = 5) and basophils (EC50 = 0.5 pmol/L, n = 3). B, Depletion of human IL-5Rα+ BMMNCs by MEDI-563 in vitro (n = 2). C, ADCC of eosinophils is not associated with ECP and EDN release (n = 2). Afuc isotype, Afucosylated isotype antibody control. Total ECP and EDN release induced by Triton X-100 was set to 100%. Cyto mix, RANTES plus eotaxin plus IL-33. Shown are representative experiments. n, Number of experiments performed. ∗Significant as determined by using the Student t test (P < .05). Journal of Allergy and Clinical Immunology 2010 125, 1344-1353.e2DOI: (10.1016/j.jaci.2010.04.004) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Eosinophil depletion in cynomolgus monkeys by MEDI-563. A, Peripheral blood eosinophil depletion in cynomolgus monkeys. B and C, Depletion of BM eosinophil precursors (Fig 4, B) and neutrophil precursors (Fig 4, C). Data indicate the average of 3 to 10 monkeys per group, and error bars represent the SD. Journal of Allergy and Clinical Immunology 2010 125, 1344-1353.e2DOI: (10.1016/j.jaci.2010.04.004) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Immunohistochemical localization of IL-5Rα–expressing cells in lung tissue. A and B, Bright field micrographs depicting MEDI-563 immunoreactive cells (red) in the bronchial mucosa (Fig 5, A) and the alveolar parenchyma (Fig 5, B). Fig 5, A, inset, High-power magnification. C, Quantification of eosinophils positive for MEDI-563 staining (± SD). D, Mast cell tryptase (green) and IL-5Rα (red). E, Red-stained eosinophils (E) in Fig 5, D, are identified through their distinct granule morphology. F, Lack of IL-5Rα staining in mast cells. Journal of Allergy and Clinical Immunology 2010 125, 1344-1353.e2DOI: (10.1016/j.jaci.2010.04.004) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions